RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
103 hedge funds and large institutions have $97M invested in RAPT Therapeutics in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 30 reducing their positions, and 39 closing their positions.
79% more call options, than puts
Call options by funds: $3.54M | Put options by funds: $1.98M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 30
0.09% less ownership
Funds ownership: 11.48% → 11.39% (-0.09%)
15% less funds holding
Funds holding: 121 → 103 (-18)
41% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 39
66% less capital invested
Capital invested by funds: $287M → $97M (-$190M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.51M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.08M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.71M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.68M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$11M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.5M |
| 3 |
Morgan Stanley
New York
|
-$4.19M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$3.77M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.81M |
RAPT Hedge Fund Activity: Q2 2024 in Review
103 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2024, worth a combined $97M — down 66% from $287M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of RAPT and 23 opened new positions — a net loss of 16 holders — while 30 trimmed existing stakes and 30 added.
The largest buyer was Millennium Management, adding an estimated $4.51M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $11M sold.
- 103 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2024, down from 121 in Q1 2024.
- Funds reported $97M of RAPT Therapeutics stock for Q2 2024, down 66% quarter-over-quarter.
- 23 funds opened new RAPT Therapeutics positions in Q2 2024 and 39 closed out, a net change of -16 holders.
- The largest RAPT Therapeutics buyer in Q2 2024 was Millennium Management, an estimated $4.51M added.
- The largest RAPT Therapeutics seller in Q2 2024 was Perceptive Advisors, an estimated $11M sold.
Based on aggregated 13F filings for Q2 2024.